U.S. pharmacies have begun carrying the Utibron Neohaler treatment-dispensing device as a long-term maintenance treatment for airflow obstruction in chronic obstructive pulmonary disease (COPD), Sunovion Pharmaceuticals announced. The powder that the device dispenses, which is a combination of  indacaterol and glycopyrrolate, is aimed at preventing bronchospasms in people with COPD.
To shine a light on the link between chronic obstructive pulmonary disease (COPD) and depression, the Lung Institute is starting an initiative to help combat depression in COPD patients. It will kick off on World Health Day, April 7. The initiative will seek to decrease the prevalence of depression…
Stem cell therapy reduced lung inflammation and improved lung damage repair in a mouse model of chronic obstructive pulmonary disease (COPD) and cystic fibrosis. The findings were presented at the Lung Science Conference recently in Estoril, Portugal. Mesenchymal stem cell (MSC) therapy uses stem cells (multipotent cells that can differentiate into a variety…
Hospital readmissions for chronic obstructive pulmonary disease (COPD) are linked to readmissions for other conditions as well as patients’ own experiences while hospitalized, such as communication with nurses, staff responsiveness, pain management and discharge information. The study reporting the findings is titled “Chronic Obstructive Pulmonary Disease Readmissions and…
The COPD Foundation has established the JW Walsh Fund to Cure COPD in honor of its late founder and director emeritus John W. Walsh, who died on March 7 this year at the age of 68. The memorial fund was created as a way to honor Walsh’s commitment to…
Pulmatrix was granted an important patent from the European Union (EU) for its proprietary iSPERSE technology, a platform for inhaled drug delivery based on unique properties developed for the treatment of lung diseases such as chronic obstructive pulmonary disease (COPD). “This new patent shows our continued ability to obtain patents that protect…
AstraZeneca and Circassia are partnering to develop and commercialize two inhaled respiratory treatments for chronic obstructive pulmonary disease (COPD) in the United States, Tudorza (aclidinium bromide) and Duaklir (aclidinium bromide). Tudorza was approved by the U.S. Food and Drug Administration (FDA) in 2012, and its marketing began that…
Metered-dose inhalers are a common device among patients with lung diseases, including chronic obstructive pulmonary disease (COPD), but users may be doing it wrong and limiting the medication’s effectiveness by getting only half the medication they need, according to two studies from Rice University. One study, “Factors Determining In…
Using Monaghan Medical’s Aerobika device as part of a treatment regimen may help reduce emergency room visits, hospital re-admissions and related costs, as well as the recurrence of exacerbations in patients with chronic obstructive pulmonary disease (COPD). The study reporting these findings, “A Real-World Study of 30-Day Exacerbation…
Chronic inflammation of the sinus cavities is more common among patients with chronic obstructive pulmonary disease (COPD) who also have bronchiectasis, underscoring the impact of chronic inflammation of the upper airways in more severe disease phases. The study, “Chronic rhinosinusitis is associated with higher prevalence and severity…
Get regular updates to your inbox.